Ahmed H. Abdelaziz

Ahmed H. Abdelaziz

Auto-generated profile, based on publicly available information

Ahmed H. Abdelaziz

Faculty of Medicine, Ain Shams University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JCO Global Oncology
Verified
Journal Article
Open access
HAHamdy A. Azim
Hamdy A. Azim
HEHagar Elghazawy
Hagar Elghazawy
Ramy Mohamed GhazyRamy Mohamed Ghazy
Ramy Mohamed Ghazy
AAAhmed H. Abdelaziz
Ahmed H. Abdelaziz
MAMarwa Abdelsalam
Marwa Abdelsalam
LKLoay Kassem
Loay Kassem
PURPOSE: Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the specific clinicopathologic features of BC in this population. Herein, we investigated the clinical profile of BC among Egyptian women. METHODS: A systematic review of studies on BC published from inception until December 2021 was performed. We explored pooled estimated proportions of different stages of BC at presentation in Egypt and other clinicopathologic features including age, menopausal status, tumor (T) and lymph node (N) stages, and biological subtypes. Data analysis was performed using meta package (R). RESULTS: Twenty-six studies were eligible for our systematic review and meta-analysis, including 31,172 BC cases. In 12 studies, including 15,067 patients with BC, the estimated mean age was 50.46 years (95% CI, 48.7 to 52.1; I2, 99%), with a pooled proportion of premenopausal/perimenopausal women of 57% (95% CI, 50 to 63; I2, 98%). Among 9,738 patients with BC, pooled proportions of stage I, II, III, and IV were 6% (95% CI, 4 to 8; I2, 90%), 37% (95% CI, 31 to 43; I2, 93%), 45% (95% CI, 42 to 49; I2, 78%), and 11% (95% CI, 9 to 15; I2, 87%), respectively. The pooled proportions of patients with T3 and T4 tumors were 21% (95% CI, 14 to 31; I2, 99%) and 8% (95% CI, 5 to 12; I2, 96%), respectively, while those with positive lymph nodes were 70% (95% CI, 59 to 79; I2, 99%). CONCLUSION: Dominance of advanced stage and young age at diagnosis represented the two main features of BC among Egyptian women. Our data may serve to guide the policymakers in Egypt as well as other countries with lower resources to prioritize the diagnostic and therapeutic needs in this context.

1 August 2021 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
ACAmarnath Challapalli
Amarnath Challapalli
SMSusan Masson
Susan Masson
PWPaul White
Paul White
NDNarges Dailami
Narges Dailami
SPSylvia Pearson
Sylvia Pearson
ABAmit Bahl
Amit Bahl
Neoadjuvant cisplatin-based combination chemotherapy improves survival in muscle-invasive bladder cancer. However, response rates and survival remain suboptimal. We evaluated the efficacy, safety, and tolerability of cisplatin plus cabazitaxel. A phase II single-arm trial was designed to recruit at least 26 evaluable patients. This would give 80% power to detect the primary endpoint, an objective response rate defined as a pathologic complete response plus partial response (pathologic downstaging), measured by pathologic staging at cystectomy (p0 = 0.35 and p1 = 0.60, α = 0.05). Objective response was seen in 15 of 26 evaluable patients (57.7%) and more than one- third of patients achieved a pathologic complete response (9/26; 34.6%). Seventy-eight percent of the patients (21/27) completed all cycles of treatment, with only 6.7% of the reported adverse events being graded 3 or 4. There were 6 treatment-related serious adverse event reported, but no suspected unexpected serious adverse reactions. In the patients who achieved an objective response, the median progression-free survival and overall survival were not reached (median follow-up of 41.5 months). In contrast, the median progression-free survival (7.2 months) and overall survival (16.9 months) were significantly worse (P = .001, log-rank) in patients who did not achieve an objective response. Cabazitaxel plus cisplatin for neoadjuvant treatment of muscle-invasive bladder cancer can be considered a well-tolerated and effective regimen before definitive therapy with higher rates (57.7%) of objective response, comparing favorably to that with of cisplatin/gemcitabine (23%-26%). These results warrant further evaluation in a phase III study.

3 January 2025 in Journal of Medical Economics
Verified
Journal Article
Open access
BPBernadette Pöllinger
Bernadette Pöllinger
AHAmin Haiderali
Amin Haiderali
MHMin Huang
Min Huang
BEBurcu Akyol Ersoy
Burcu Akyol Ersoy
AAAhmed H. Abdelaziz
Ahmed H. Abdelaziz
GEGihan Hamdy Elsisi
Gihan Hamdy Elsisi
The cost-effectiveness of neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab compared to neoadjuvant chemotherapy plus placebo followed by adjuvant placebo was assessed in high-risk, early-stage, triple-negative breast cancer patients from an Egyptian societal perspective over a lifetime horizon. A 4-state Markov cohort model was developed to compare the cost-effectiveness of pembrolizumab + chemotherapy/pembrolizumab vs chemotherapy alone for the treatment of high-risk, early-stage, triple-negative breast cancer. The model simulated the clinical course of high-risk, early-stage, triple-negative breast cancer across 4 health states: event-free survival, locoregional recurrence, distant metastasis, and death. Clinical inputs for the simulation were derived from modeling of efficacy and safety data collected in the KEYNOTE-522 trial. Direct medical costs and indirect costs were reported in 2022 Egyptian pounds [EGP] and converted to US dollars ($). Probabilistic and deterministic sensitivity analyses were conducted to assess the robustness of model results. Compared with chemotherapy alone, pembrolizumab + chemotherapy/pembrolizumab led to expected gains of 2.92 life years and 2.25 quality-adjusted life years, respectively, while increasing overall treatment costs by EGP 491695 [$102436]. Incremental costs per year gained were EGP 218285 [$45476] per quality-adjusted life year and EGP 168223 [$35046] per life year, both of which were lower than the 2022 Egyptian cost-effectiveness threshold of EGP 398439 [$83008]. The findings of sensitivity analyses indicated that the model was robust across a range of inputs and assumptions. In Egypt, pembrolizumab + chemotherapy/pembrolizumab is a cost-effective treatment for high-risk, early-stage, triple-negative breast cancer when considering health-related quality of life and years of life gained.

23 October 2018 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
AAA.H. Abdelaziz
A.H. Abdelaziz
AAA.M. Abdou
A.M. Abdou
CHC.N. Habeeb
C.N. Habeeb
Background: Breast cancer is the most common type of female cancer in Egypt and world wide. Most of the cases present as locally advanced or metastatic rather than early stages in Egypt. There is no data to assess waiting times in the Egyptian breast cancer patient journey from developing first symptom until initiating treatment.

1 April 2022 in International Journal of Cancer and Biomedical Research
Verified
Journal Article
Closed access
PDF file
NHNervana Hussien
Nervana Hussien
MEMai Mohamed Ezzeldin
Mai Mohamed Ezzeldin
AAAhmed H Abdelaziz
Ahmed H Abdelaziz
HAHaitham Shaheen Ahmed
Haitham Shaheen Ahmed
MEMohamed El-Kassas
Mohamed El-Kassas
SASoha Ahmed
Soha Ahmed
Background: The COVID-19 epidemic has wreaked havoc on individuals of all ages throughout the world. I In unprecedented time frame, its vaccination has been produced and made available to the general population. However, due to varying levels of its acceptance, vaccination did not gain widespread adoption. Aim: We aimed to measure the perception and experience of oncologists towards COVID-19 vaccination in cancer patients on active therapy. Methods: A cross-sectional survey with a self-administered questionnaire was circulated among oncology specialists in Egypt between September – and December 2021. Results: A total of 83 respondents participated of which 59% had more than 10 years of experience in the oncology field. The majority of the respondents 75 (90.4%) recommended giving the vaccine once available in case of hormonal treatment meanwhile the lowest percentage 32 (38.5%) was for anti CD20 monoclonal antibody, either as a single agent or combined with chemotherapy. Choices of 49 (59%), 46 (55%), and 43 (51.8%) to vaccinate patients on active treatment with cytotoxic chemotherapy, MoAb (except anti CD20), and immunotherapy respectively were reported. The inactivated COVID-19 virus vaccine was recommended by 39 (47%), followed by Vector vaccines in 20 (24.1%), 8 (9.6%) for the messenger RNA (mRNA) vaccines, while 16(19.3%) of them were undecided. Thirty-nine (47%) of the participants reported that patients on active treatment developed side effects from vaccination. The most conveyed side effects were fatigue in 34 (87%), fever or a local reaction each in 28 (71.8%), headache and myalgia equally in 19 (48.7%), and chills in 11 (28.2%), and myalgia in10 (25.6 %). Conclusion: Strategies to address the practicality of dealing with vaccination in cancer patients are needed. Emphasis on the installation of the latest data in caring for this population and increased awareness of the services provided is crucial. Surveys are a useful tool reflecting real-world practice.